PLA 85 Hospital, which is a Liver Disease Center. The trial will evaluate the safety and efficacy in lowering the incidence of tumor recurrence and metastasis by means of autologous immune cell therapy in primary HCC patients following standard tumor resection and TACE chemotherapy.
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Cellular-Biomedicine-Group-Announces-Completion-of/ArticleNewsFeed/Article/detail/820998?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Cellular-Biomedicine-Group-Announces-Completion-of/ArticleNewsFeed/Article/detail/820998?ref=25
No comments:
Post a Comment